Antimmune is a life science company founded in 2011 by Dr. T.A. Luijkx in close collaboration with UMCN, Nijmegen.
Antimmune discovered and filed a patent on a novel biologics platform to induce antigen-specific tolerance. As this biologic platform can be used to develop therapeutics to stop any autoimmune disease, the potential is very high.
The development of such a therapeutic vaccine is a long process, including research and expensive clinical trails. Therefore, Antimmune BV seeks pharmaceutical partners for in-licensing and further development of the therapeutic vaccines.